G2GBio (456160) recorded a surge of more than 20% on the 23rd, despite a decline in the KOSDAQ market, showing a movement clearly distinct from the overall market trend.

On the day, G2GBio closed at 49,600 won, up 8,400 won (+20.39%) from the previous trading day. On the same day, the KOSDAQ index finished at 751.69, down 12.41 points (-1.62%) from the previous session. Even as weakness spread across the market, this stock alone posted a standout gain.

The fact that the share price has come close to the 50,000-won mark as a result of this surge also draws attention. Based on the closing price, only 400 won remains before reaching 50,000 won. Accordingly, attention is focused on whether the upward trend can continue in the new trading week starting after the weekend. Whether the strong buying pressure seen in the previous session will persist, or whether profit-taking moves will emerge following the sharp short-term rise, will be key points to watch.

The catalyst came earlier. G2GBio announced on the 19th that it had signed a platform evaluation contract with The United Bio-Technology (Hengqin) Co., Ltd. (UBT), a pharmaceutical company based in China, for the development of long-acting injectable drugs. Under the agreement, UBT will provide specific candidate substances to be evaluated using G2GBio's InnoLAMP platform to assess the feasibility of developing long-acting injectables.

Attention is now focused on whether the upward trend will continue into the new week, building on the previous session's surge, and whether share price volatility will expand as the stock approaches the 50,000-won level.

[※ This article is for investment reference purposes only and does not recommend the purchase or sale of any specific stock. The final judgment and responsibility for investments rest with the investor.]